Jounce Therapeutics Inc

Jounce Therapeutics Inc

JNCE - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$98.95M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Jounce Therapeutics IncJounce Therapeutics Inc-1.9--28%1.90.1
$3.79

Current Fair Value

101.8% upside

Undervalued by 101.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$98.95 Million
Enterprise Value$-41,597,260.00
Earnings per Share$-0.99
Beta0.75
Outstanding Shares51,676,000

Return

Return on Equity-27.81%ROE
Return on Assets-23.96%
Return on Invested Capital-27.64%

Valuation & Multiples

P/E Ratio-1.9P/E Ratio
PEG0PEG
Price to Sales1.88Price to Sales
Price to Book Ratio0.63Price to Book Ratio
Enterprise Value to Revenue-0.51
Enterprise Value to EBIT0.8
Enterprise Value to Net Income0
Total Debt to Enterprise-0.24
Debt to Equity0.05Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Jounce Therapeutics Inc

CEO: Richard Murray

Jounce Therapeutics Insider Information FAQ

In the latest 13F quarter on Stockcircle, 4 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.